查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609144

自然杀手细胞疗法市场：按治疗方法、方法、应用和最终用户 - 2025-2030 年全球预测

Natural Killer Cell Therapeutics Market by Therapeutics (NK Cell Directed Antibodies, NK Cell Therapies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自然杀手细胞疗法市场2023年估值为53.1亿美元，预计到2024年将达到60.2亿美元，复合年增长率为11.94%，到2030年将达到117.1亿美元。

自然杀手 (NK) 细胞疗法是免疫疗法的一个动态前沿，重点是利用先天免疫系统靶向并消灭癌细胞和其他病原体的能力。这些治疗方法涵盖多种治疗方法，包括在癌症治疗、感染疾病治疗和自体免疫疾病管理中的应用。对 NK 细胞疗法的需求源于 NK 细胞在无需事先致敏的情况下在身体中巡逻并对抗威胁的天然能力，这为增强现有免疫疗法提供了一种有前途的方法。它的应用也扩展到个人化医疗，开发针对患者的治疗方法可以达到更有效的治疗结果。最终用途主要涵盖医疗机构、研究实验室和生物製药公司，每家公司都寻求利用和提高 NK 细胞的临床应用能力。

主要市场统计
基准年[2023] 53.1亿美元
预计年份 [2024] 60.2亿美元
预测年份 [2030] 117.1亿美元
复合年增长率（%） 11.94%

该市场的成长是由基因工程的进步、癌症和感染疾病的增加以及生物技术研发投资的激增所推动的。最新的商机来自人工智慧和机器学习的合作以优化 NK 细胞功能，以及学术界和工业界之间的合作以实现快速创新。建议强调投资重组基因技术并探索联合治疗以提高疗效。然而，该市场面临开发成本高、监管环境严格以及对 NK 细胞机制了解有限等挑战，导致进展缓慢。此外，患者反应的可变性使治疗开发更加复杂。创新研究可以集中在透过 CRISPR 基因编辑增强 NK 细胞的细胞毒性、开发现成的同种异体 NK 细胞疗法以及应用资料分析来预测患者特异性反应。该市场竞争激烈但分散，研发活动强劲，许多新兴企业瞄准利基应用。寻求引领市场的公司必须培养策略伙伴关係，优先考虑以患者为中心的方法，并灵活应对监管变化。 NK 细胞疗法正在改变治疗范式，并突显现代医学成长和创新的关键领域。

市场动态：快速发展的自然杀手细胞疗法市场的关键市场洞察

自然杀手细胞治疗市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症盛行率上升
    • 副作用较少的标靶治疗趋势
    • 免疫疗法的显着改进
  • 市场限制因素
    • 自然杀手细胞治疗药物的高成本
  • 市场机会
    • 持续研发改良自然杀手细胞治疗药物
    • 开发新型自然杀手细胞治疗药物的优势投资
  • 市场挑战
    • 自然杀手细胞疗法的复杂性

波特五力：驾驭自然杀手细胞治疗市场的策略工具

波特的五力框架是了解自然杀手细胞治疗药物市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自然杀手细胞治疗市场的外部影响

外部宏观环境因素在塑造自然杀手细胞治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解自然杀手细胞治疗市场的竞争状况

对自然杀手细胞治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵自然杀手细胞疗法市场供应商的绩效评估

FPNV定位矩阵是评估自然杀手细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划自然杀手细胞治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对自然杀手细胞治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症发生率正在上升
      • 副作用最小的标靶治疗趋势
      • 免疫疗法的重大进展
    • 抑制因素
      • 自然杀手细胞治疗药物的高成本
    • 机会
      • 持续研究和开发以改进自然杀手细胞疗法
      • 新开发自然杀手细胞治疗药物的有利投资
    • 任务
      • 与自然杀手细胞治疗药物相关的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自然杀手细胞治疗市场

  • 针对 NK 细胞的抗体
  • NK细胞疗法

第七章自然杀手细胞治疗药物市场分析

  • 抗体依赖性细胞介导的细胞毒性（ADCC）
  • 双特异性抗体

第八章自然杀手细胞治疗药物市场：依应用分类

  • 急性感染疾病
  • 癌症
  • 消化系统疾病
  • 免疫增生性疾病

第九章自然杀手细胞治疗药物市场：依最终使用者分类

  • 医院
  • 研究/学术机构
  • 专科诊所

第十章美洲自然杀手细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区自然杀手细胞治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲自然杀手细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Acepodia Inc.
  • Affimed NV
  • BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • Celgene Corporation by Bristol-Myers Squibb Company
  • Celularity Inc.
  • Century Therapeutics, Inc.
  • Cytovac A/S
  • Dragonfly Therapeutics, Inc.
  • EMERcell
  • Fate Therapeutics, Inc.
  • Fortress Biotech, Inc.
  • Gamida Cell Ltd.
  • Glycostem Therapeutics BV
  • iCell Gene Therapeutics LLC
  • ImmunityBio, Inc. by NantWorks LLC
  • Innate Pharma SA
  • Kiadis Pharma NV by Sanofi SA
  • Merck KGaA
  • MiNK Therapeutics, Inc.
  • Multimmune GmbH
  • Nkarta, Inc.
  • PersonGen BioTherapeutics
  • Phio Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-5C6F41F5AFEC

The Natural Killer Cell Therapeutics Market was valued at USD 5.31 billion in 2023, expected to reach USD 6.02 billion in 2024, and is projected to grow at a CAGR of 11.94%, to USD 11.71 billion by 2030.

Natural Killer (NK) Cell Therapeutics represent a dynamic frontier within immunotherapy, focusing on leveraging the innate immune system's ability to target and destroy cancer cells and other pathogens. The scope of these therapeutics encompasses a variety of treatment modalities, including cancer therapies, infectious disease treatments, and applications in auto-immune disorder management. The necessity for NK cell therapeutics arises from their natural ability to patrol the body and combat threats without prior sensitization, offering a promising approach to enhance existing immune therapies. The application extends into personalized medicine, where patient-specific treatment regimens can be developed for more effective outcomes. End-use primarily spans healthcare facilities, research laboratories, and biopharmaceutical companies, each seeking to harness and refine NK cell capabilities for clinical use.

KEY MARKET STATISTICS
Base Year [2023] USD 5.31 billion
Estimated Year [2024] USD 6.02 billion
Forecast Year [2030] USD 11.71 billion
CAGR (%) 11.94%

Growth in this market is driven by advancements in genetic engineering, increasing incidences of cancer and infectious diseases, and burgeoning investment in biotech R&D. Latest opportunities stem from collaborations with artificial intelligence and machine learning to optimize NK cell function, as well as partnerships between academia and industry for rapid innovation. Recommendations emphasize investing in genetic modification technologies and exploring combination therapies to enhance efficacy. However, the market faces challenges such as high development costs, stringent regulatory landscapes, and limited understanding of NK cell mechanisms, which can slow progress. Moreover, the variability in patient response further complicates therapeutic development. Innovative research could focus on enhancing NK cell cytotoxicity through CRISPR gene editing, developing off-the-shelf allogeneic NK cell therapies, and applying data analytics to predict patient-specific responses. The market is competitive yet fragmented, marked by intense R&D activities and numerous start-ups targeting niche applications. Companies looking to lead should foster strategic partnerships, prioritize patient-centric approaches, and remain agile to regulatory changes. As the therapeutic landscape evolves, NK cell therapeutics stand to revolutionize treatment paradigms, highlighting a pivotal area of growth and innovation in modern medicine.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Natural Killer Cell Therapeutics Market

The Natural Killer Cell Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer worldwide
    • Inclination towards targeted therapies with minimal side effects
    • Significant improvements in immunotherapy
  • Market Restraints
    • High cost associated with natural killer cell therapeutics
  • Market Opportunities
    • Ongoing R&D to improve natural killer cell therapeutics
    • Favorable investments for development of novel natural killer cell therapeutics
  • Market Challenges
    • Complexity associated with natural killer cell therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Natural Killer Cell Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Natural Killer Cell Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Natural Killer Cell Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Natural Killer Cell Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Natural Killer Cell Therapeutics Market

A detailed market share analysis in the Natural Killer Cell Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Natural Killer Cell Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Natural Killer Cell Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Natural Killer Cell Therapeutics Market

A strategic analysis of the Natural Killer Cell Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Natural Killer Cell Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acepodia Inc., Affimed N.V., BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc., Celgene Corporation by Bristol-Myers Squibb Company, Celularity Inc., Century Therapeutics, Inc., Cytovac A/S, Dragonfly Therapeutics, Inc., EMERcell, Fate Therapeutics, Inc., Fortress Biotech, Inc., Gamida Cell Ltd., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio, Inc. by NantWorks LLC, Innate Pharma S.A., Kiadis Pharma N.V. by Sanofi S.A., Merck KGaA, MiNK Therapeutics, Inc., Multimmune GmbH, Nkarta, Inc., PersonGen BioTherapeutics, Phio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Natural Killer Cell Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics, market is studied across NK Cell Directed Antibodies and NK Cell Therapies.
  • Based on Approaches, market is studied across Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies.
  • Based on Application, market is studied across Acute Infectious Diseases, Cancer, Gastrointestinal Diseases, and Immunoproliferative Disorders.
  • Based on End User, market is studied across Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide
      • 5.1.1.2. Inclination towards targeted therapies with minimal side effects
      • 5.1.1.3. Significant improvements in immunotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with natural killer cell therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to improve natural killer cell therapeutics
      • 5.1.3.2. Favorable investments for development of novel natural killer cell therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity associated with natural killer cell therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Natural Killer Cell Therapeutics Market, by Therapeutics

  • 6.1. Introduction
  • 6.2. NK Cell Directed Antibodies
  • 6.3. NK Cell Therapies

7. Natural Killer Cell Therapeutics Market, by Approaches

  • 7.1. Introduction
  • 7.2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  • 7.3. Bispecific Antibodies

8. Natural Killer Cell Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Infectious Diseases
  • 8.3. Cancer
  • 8.4. Gastrointestinal Diseases
  • 8.5. Immunoproliferative Disorders

9. Natural Killer Cell Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research & Academic Institutes
  • 9.4. Specialty Clinics

10. Americas Natural Killer Cell Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Natural Killer Cell Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Natural Killer Cell Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acepodia Inc.
  • 2. Affimed N.V.
  • 3. BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • 4. Celgene Corporation by Bristol-Myers Squibb Company
  • 5. Celularity Inc.
  • 6. Century Therapeutics, Inc.
  • 7. Cytovac A/S
  • 8. Dragonfly Therapeutics, Inc.
  • 9. EMERcell
  • 10. Fate Therapeutics, Inc.
  • 11. Fortress Biotech, Inc.
  • 12. Gamida Cell Ltd.
  • 13. Glycostem Therapeutics B.V.
  • 14. iCell Gene Therapeutics LLC
  • 15. ImmunityBio, Inc. by NantWorks LLC
  • 16. Innate Pharma S.A.
  • 17. Kiadis Pharma N.V. by Sanofi S.A.
  • 18. Merck KGaA
  • 19. MiNK Therapeutics, Inc.
  • 20. Multimmune GmbH
  • 21. Nkarta, Inc.
  • 22. PersonGen BioTherapeutics
  • 23. Phio Pharmaceuticals Inc.
  • 24. Regeneron Pharmaceuticals Inc.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. NATURAL KILLER CELL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NATURAL KILLER CELL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NATURAL KILLER CELL THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL DIRECTED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ACUTE INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY IMMUNOPROLIFERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023